NKMAX Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

NKMAX's earnings have been declining at an average annual rate of -8.7%, while the Biotechs industry saw earnings growing at 12.4% annually. Revenues have been growing at an average rate of 7.6% per year.

Anahtar bilgiler

-8.7%

Kazanç büyüme oranı

-5.2%

EPS büyüme oranı

Biotechs Sektör Büyümesi11.7%
Gelir büyüme oranı7.6%
Özkaynak getirisi-19.4%
Net Marj149.3%
Son Kazanç Güncellemesi31 Mar 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Introducing NKMAX (KOSDAQ:182400), A Stock That Climbed 96% In The Last Year

Feb 10
Introducing NKMAX (KOSDAQ:182400), A Stock That Climbed 96% In The Last Year

Gelir ve Gider Dağılımı

NKMAX nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

KOSDAQ:A182400 Gelir, gider ve kazançlar (KRW Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Mar 2410,47515,64443,1928,062
31 Dec 2310,7695,26148,2779,441
30 Sep 2310,945-66,60943,7739,819
30 Jun 2310,997-38,99938,4909,950
31 Mar 2310,728-54,67735,89610,400
31 Dec 2211,263-53,50535,8649,895
30 Sep 2211,705-60,70537,8549,765
30 Jun 2212,159-50,88237,0079,990
31 Mar 2212,771-50,55836,04710,235
31 Dec 2113,020-50,33636,1419,355
30 Sep 2112,605-40,89535,1268,898
30 Jun 2111,959-49,14834,3118,682
31 Mar 2111,234-45,05033,9327,788
31 Dec 2010,372-41,43931,4908,189
30 Sep 209,416-45,71927,1189,538
30 Jun 209,169-40,78724,1878,738
31 Mar 208,722-16,10721,2777,522
31 Dec 198,749-11,42918,9216,505
30 Sep 197,825-5,34415,9804,932
30 Jun 197,085-4,27814,4004,300
31 Mar 196,824-22,05814,1744,479
31 Dec 186,269-20,45313,5774,655
30 Sep 185,913-20,31814,6425,120
30 Jun 185,677-18,88514,9175,203
31 Mar 185,155-17,47314,3955,118
31 Dec 174,830-16,63213,8535,093
30 Sep 177,253-9,96912,6683,656
30 Jun 177,091-5,86611,4313,545
31 Mar 176,855-4,9609,7683,688
31 Dec 166,876-4,8379,1203,913
30 Sep 164,140-7,2287,8383,835
30 Jun 163,578-8,3907,2423,769
31 Mar 163,228-5,5935,4043,108
31 Dec 152,513-5,3745,2232,724
30 Sep 152,001-5,9705,3262,597
30 Jun 151,777-5,8504,4422,471
31 Mar 151,732-6,1664,2252,484
31 Dec 141,678-5,8403,7602,313
31 Dec 131,503-3,1812,562732

Kaliteli Kazançlar: A182400 has a high level of non-cash earnings.

Büyüyen Kar Marjı: A182400 became profitable in the past.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: A182400 has become profitable over the past 5 years, growing earnings by -8.7% per year.

Büyüme Hızlandırma: A182400 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Kazançlar vs. Sektör: A182400 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (13.4%).


Özkaynak Getirisi

Yüksek ROE: A182400's Return on Equity (-19.4%) is considered low.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin